Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone PK for OPAT in Enterococcus Faecalis Infective Endocarditis
NCT03681431Phase 2Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Apr 2018
- Primary completion
- Apr 2019
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ceftriaxone in Enterococcus faecalis infective endocarditis (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Serum levels after 24 hours. Started Apr 2018; status: completed.
02
Drugs
ceftriaxone
03
Conditions
Enterococcus faecalis infective endocarditis
Beyond the preview
Go deeper on NCT03681431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681431.